FDC Ltd.
FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally. The company offers pharmaceutical formulations for various therapeutic segments, including anti-infectives, gastrointestinal, ophthalmology, vitamins, minerals, dietary supplements, cardiovascular and anti-diabetic therapies, respiratory care, gynaecology, dermatology, and analgesics in the form of tablets, capsules, oral liquids, ophthalmic drops, topical preparations, and paediatric-friendly solutions. It also provides functional food, such as flavoured ORS powders, ready-to-drink electrolyte beverages, vitamin-enriched supplements, antioxidant blends and protein-fortified drinks; and various active pharmaceutical ingredients. The company sells its products under the Zifi, Zefu, Zocon, Amodep-AT, Zathrin, Vitcofol, Ziglim, Ziglim-M,Mycoderm, Zoxan, Cotaryl, Pyrimon DF, Zipod, Electral, and Enerzal brands. It also exports its products to approximately 50 countries. FDC Limited was founded in 1936 and is based in Mumbai, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Comfortable interest coverage of 84.5x
Concerns0
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (₹ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (₹ Crores, last 1 year)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | ₹2.07 K Cr | — | ₹274.00 Cr | — | — | 12.0% | 8.0% | -10.7% |
Showing the latest year only. Sign up free for the full history.
Financial Statements
Income statement, balance sheet, and cash flow (₹ Crores, as reported)
Showing the latest year only. Sign up free for the full history.
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 2,045 |
| Total Expenses | 1,770 |
| EBIT / Operating Profit | 275 |
| OPM % | 13% |
| Other Income | 107 |
| Finance Costs | 4 |
| Depreciation & Amortisation | 59 |
| Profit Before Tax | 318 |
| Tax % | - |
| Net Profit / PAT | 236 |
| EPS (₹) | 14.52 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| FDC Ltd.this co. | ₹6.39 K Cr | ₹2.07 K Cr | 27.00 | 2.61 | 14.22 | 8.0% |
| Sun Pharmaceutical Industries Ltd. | ₹4.15 L Cr | ₹23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | ₹1.71 L Cr | ₹9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | ₹1.33 L Cr | ₹9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | ₹1.17 L Cr | ₹19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | ₹1.05 L Cr | ₹8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | ₹1.00 L Cr | ₹2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | — | ₹3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |